×

AI drug developer Isomorphic raises $5 billion in Series C round

By Thomson Reuters Nov 17, 2026 | 7:43 AM

Nov 17 (Reuters) – Isomorphic Labs said on Tuesday it has raised $5 billion in a Series C funding round co-led by Greenoaks ​and Sequoia Capital, as the Alphabet-backed ‌AI drug discovery company works to move its first drug candidates into clinical trials.

The company, which was spun out of Google DeepMind in 2021, declined to ‌share ​its valuation. The funding comes ⁠about six months after ⁠it raised $2.1 billion in a Series B round led by Thrive Capital.

Here are more details:

• Andreessen Horowitz and other new investors joined ​the round, while Alphabet made a significant investment and other existing backers, including Thrive, ⁠MGX and GV, also ⁠participated

• “This round enables us to accelerate ​our progress: building foundational biology models, deepening our systemic ​disease understanding, and driving our first therapeutic ‌programs towards clinical trials to deliver tangible impact for patients,” Isomorphic founder and CEO Demis Hassabis said

• The company is developing its IsoDDE ⁠drug design engine, which uses AI to design new drugs, predict their properties and refine them before ⁠scientists decide ‌on the candidates to make and ⁠test

• Isomorphic said it has ​seen positive ‌pre-clinical results in internal oncology ​and immunology ⁠programs and with partners, “setting the stage for clinical entry”

• The company lists Novartis, Eli Lilly and Johnson & Johnson as its partners, according to its website

(Reporting by Prathik Jayaprakash in Bengaluru; Editing by ​Leroy Leo)